U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin

By Ben ComerChief Editor, Life Science Leader
Monday, April 3, 2023

Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S. Continue Reading..

Making The Right Deal For Biohaven
3/1/2023

Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.
Translating Nobel Prize Winning Science Into Medicine
3/1/2023

2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.
Commercialization Or Bust?
3/1/2023

If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?
Choosing Your Battles
2/1/2023

Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
With Fundraising, A Track Record Matters: GeoVax's David Dodd
2/1/2023

Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.
Why Takeda Is Focusing So Much On Plasma-Derived Therapies
2/1/2023

Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
Verve Therapeutics: How To Build A Gene Editing Biotech
1/3/2023

Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.
Peter Marks: Prioritizing Better Communication And Faster Product Reviews
1/3/2023

In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.
The Next Big Thing
1/3/2023

Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?

Ben Comer

Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.